Piper Sandler raised the firm’s price target on Edwards Lifesciences (EW) to $98 from $95 and keeps an Overweight rating on the shares. The firm is updating a handful of its models to adjust for preliminary Q4 results and initial full year 2026 guidance announcements from this past week or so.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $95 from $92 at UBS
- Edwards Lifesciences price target raised to $90 from $87 at Baird
- Edwards Lifesciences price target raised to $104 from $103 at Barclays
- Edwards Lifesciences Stock (EW) Falls as FTC Wins Ruling to Block JenaValve Deal
- Edwards Lifesciences will not acquire JenaValve, updates FY26 guidance